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INTRODUCTION 
Human Immunodeficiency virus (HIV) belongs to the family 
Retroviridae and sub-family Lentivirinae. HIV-1 causes the Acquired 
Immunodeficiency Syndrome (AIDS).  By definition, any HIV infected 
individual with a CD4 T cell count of less than 200/microliter has AIDS, 
regardless of the presence of symptoms or opportunistic diseases.   AIDS 
was first recognized in the Unites States in 1981, when the US Centres 
for Disease Control and Prevention (CDC) reported the unexplained 
occurrence of Pneumocystis carinii (jirovecii) pneumonia in five 
previously healthy homosexual men in Los Angeles and of Kaposi’s 
sarcoma in twenty-six previously healthy homosexual men in New York 
and Los Angeles.  In 1983, Human Immunodeficiency virus was isolated 
from a patient with lymphadenopathy and in 1984 it was demonstrated 
clearly to be the causative agent of AIDS. 
Early therapeutic goals focused on prolongation of life by 
aggressive treatment of often fatal opportunistic infections, such as 
Pneumocystis carinii (jirovecii) pneumonia.  Descriptions of specific HIV 
related myocarditis and cardiomyopathy appeared during the 1980s and 
overall mortality fell with improved prophylactic regimens against 
opportunistic infection and clinical surveillance programmes.  In the mid 
1990s the advent of combination highly active antiretroviral therapy 
(HAART) made a major impact on the morbidity and mortality of HIV 
patients.  Combination therapy reduces viral replication, delays disease 
 2
progression, and prolongs survival, while limiting development of viral 
resistance.  Survival to 40-50 years is no loner unusual and coronary 
artery disease, either de novo or as an iatrogenic consequence of newer 
treatment regimens, is emerging as an important problem.  Recent studies 
report increased rates of coronary events in HIV patients or in HIV 
patients receiving HAART.40,41Protease inhibitors, a main component of 
HAART, induce deleterious metabolic effects such as dyslipidemia and 
insulin resistance.42 
HIV infection is characterized by an acquired, irreversible, 
profound immunosuppression that predisposes patients to multiple 
opportunistic infections, malignancies, and progressive dysfunction of 
multiple organ systems.  HIV specifically infects and gradually depletes 
CD4+ lymphocytes but may also affect other cell types, including 
monocytes/macrophages, endothelial cells, glial cells, intestinal epithelial 
cells, and possible neurons.  Studies have suggested that HIV may exhibit 
a cardiac tropism, but the heart may also be affected by other 
opportunistic viruses, fungi and protozoa.  Cardiac disease associated 
with HIV may therefore be multi factorial, and can be caused by 
infectious or neoplastic complications or their treatments, any of the 
established causes of cardiac disease in other patient populations, or by 
HIV infection of the myocardium itself.4 So, the knowledge of the 
relative frequency of each form of heart disease in patients with HIV is 
constantly evolving. 
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AIMS AND OBJECTIVES 
 
¾ To find out the prevalence of cardiac disease in HIV positive 
individuals. 
¾ To assess the correlation between the development of cardiac 
disease and the CD4 lymphocyte count in HIV positive individuals. 
¾ To determine the correlation between clinical findings and 
echocardiographic cardiac involvement in HIV positive 
individuals. 
¾ To know the common cardiac manifestations in the study group.  
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REVIEW OF LITERATURE 
EPIDEMIOLOGY 
The HIV pandemic enters its third decade and the resultant 
Acquired immunodeficiency syndrome (AIDS) is a global health crisis 
with approximately 36 million people affected worldwide.  In 2004, the 
World Health Organisation estimated that there were 39.4 million people 
living with HIV/AIDS, 4.9 million new infections and 3.1 million 
deaths.43 The cumulative death toll since epidemic began is over 20 
million, the vast majority occurring in sub-Saharan Africa where over 13 
million children have been orphaned. A total of 64% of all persons with 
HIV lives in sub – Saharan Africa with south Africa accounting for one 
third of the AIDS deaths globally.  Since 2002, the steepest increase has 
been in East Asia (50%) attributable largely to the epidemic occurring in 
China and in Eastern Europe and Central Asia (40%). In Vietnam, 
Thailand, Cambodia, Nepal and Myanmar, HIV is now well established.    
In India, it is estimated that 5.1 million persons are currently infected; in 
Tamil Nadu 50% of the sex workers are infected and in Manipur over 5% 
of pregnant women are positive.  In Northern India, HIV in well 
established in injection drug users, of whom 25 to 50% are infected. 
Given that Asia is home to 60% of world’s population, these changes can 
have huge implications. The disease is now the principal cause of death in 
young adults in many parts of the USA and Europe. 
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The Mortality rate among patients with HIV infection has 
decreased markedly in the United States since the introduction of 
HAART. For example, in the HIV outpatient study, mortality among 
1255 patients with at least  CD4+ count <100 cells/mm3 declined from 
29.4 to 8.8 per 100 patient years between 1995 and the second quarter of 
1997.44 This decline coincided with the initiation of protease inhibitors  
for 80% of the study population.  Similarly, in a European cohort study of 
4270 patients who had had a CD4+ count < 500 cells/mm3, mortality fell 
from 23.3 to 4.1 per 100 patient – years between mid-1995 and late 1997 
to early 1998.45 The decrease in mortality in these studies was 
accompanied by a decline the incidence of opportunistic infections44 and 
correlated with the intensity of antiretroviral therapy.45 
LITERATURE REVIEW 
Cardiac involvement in AIDS was first reported in 1983 in a 
postmortem description of a 24 year old woman of Haitian origin with 
multiple complications of AIDS, including Kaposi’s sarcoma involving 
the entire anterior cardiac wall without pericardial effusion.8 
Subsequently, cardiac involvement in patients with HIV infection has 
been described in multiple necropsies, clinical and echocardiographic 
series.  Almost any agent that can cause disseminated infection in patients 
with AIDS may involve the myocardium, but clinical evidence of cardiac 
disease is usually overshadowed by manifestations in other organs, 
primarily the brain and lungs.  Thus, the number of patients with AIDS 
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and cardiac involvement at necropsy greatly exceeds the number with 
significant cardiac disease during life.  Estimates of prevalence vary 
widely from 28-73% 1 according to the screening methods elected.  
Although exact data are unavailable, conservative estimates derived from 
European and US series indicate cardiac morbidity and mortality in HIV 
patients of 6-10% and 1-9% respectively.3, 4   
MYOCARDIAL DISEASE 
The first case of rapidly fatal, dilated cardiomyopathy in a patient 
with AIDS was described in 1986.  Among patients with dilated 
cardiomyopathy, HIV is the underlying cause in 4% 6, prognosis is poor 
and patients with HIV related cardiomyopathy have a mortality hazard 
ratio of 4.0 in comparison with controls with idiopathic dilated 
cardiomyopathy.  Dilated cardiomyopathy affects 10-20% of those with 
HIV infection and accounts for approximately a third of HIV related 
deaths.7 Median survival are 101 days in patients with left ventricular 
dysfunction compared with 472 days in HIV patients with a normal 
echocardiogram at the same stage of infection.  Similarly, a longitudinal 
prospective study of HIV infected infants and children found that left 
ventricular dysfunction was a significant predictor of overall mortality, 
even after adjustment for age, height, CD4 cell count, and progressive 
neurological disease.9 
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Mechanisms 
Dilated cardiomyopathy occurs late in the course of HIV infection 
and is usually associated with a significantly reduced CD4 count.16 
Pathological examination shows endocardial fibrosis and mural thrombus, 
particularly at the apex and histological evidence of myocyte hypertrophy 
and degeneration with increased interstitial and endocardial fibrillar 
collagen, often associated with evidence of previous myocarditis.The 
pathogenesis remains uncertain: speculated causes include direct 
infection of the heart by HIV itself, toxic effects of antiretroviral therapy, 
effects of circulating or systemic toxins, infection of the heart by 
opportunistic pathogens, toxicity of alcohol, illicit or self prescribed 
substances, and nutritional disorders.36 Indeed, several of these factors 
may operate in an individual patient. 
Direct correlation between histological cardiac abnormalities and 
clinical or functional heart muscle disease has not been established, 
making it difficult to determine whether cardiomyopathy is related 
directly to the presence of the virus or triggering of overt myocarditis.21 
In one prospective study of 952 asymptomatic HIV positive patients, an 
echocardiographic diagnosis of dilated cardiomyopathy was made in 
76(8%) patients with a mean annual incidence of 15.9/1000 patients. All 
patients with echocardiographic abnormalities underwent myocardial 
biopsy; myocarditis was present in 63 (83%) of the patients with dilated 
cardiomyopathy and 36 (57%) of these had a positive hybridization signal 
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of HIV.10 Co-infection with coxsackie virus, cytomegalovirus, and 
Epstein-Barr virus was also noted in may cases.10  HIV virions may infect 
cardiac myocytes resulting in injury as a result of direct toxicity or 
activation of multifunctional cytokines (for example, endothelin-1, 
tumour necrosis factor-α, interleukin-6).  The mode of entry of HIV into 
myocytes remains unclear since they are CD4 receptor negative.  Further 
putative mechanisms of tissue damage include post viral autoimmunity 
and immune system dysregulation, adverse effects of viral proteins 
(including apoptosis), interference with β adrenergic stimulation, and 
transcriptional activation of cellular genes. 
HIV infection may persist in reservoir cells within the myocardium 
and cerebral cortex despite anti-retroviral therapy and be associated with 
chronic release of cytotoxic cytokines.  Thus, patients with 
encephalopathy have a higher likelihood of death from congestive heart 
failure than non encephalopathic controls (hazard ration 3.4).17 
Malnutrition and wasting are also important predictors of cardiac 
morbidity and mortality in HIV infection.  There is a relation between 
trace element deficiency and cardiomyopathy, and the cardiac virulence 
of coxsackie virus is enhanced by selenium deficiency.  Indeed, selenium 
supplementation has been shown to improve cardiac dysfunction in AIDS 
patients.36 
Echocardiography 81 is helpful in the diagnosis of dilated 
cardiomyopathy and may also detect diastolic dysfunction in early 
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disease.25,35 Computed tomography or magnetic resonance imaging may 
help to clarify the etiology, especially in cases secondary to neoplastic 
infiltration.  The need for routine myocardial biopsy is controversial and 
associated risks are significant—sensitivity is low, especially in patchy 
lesions, and beyond research protocols its use is limited to patients with 
extensive cardiac damage with no identifiable cause. 
Treatment for HIV related cardiomyopathy is generally similar to 
that for non-ischemic cardiomyopathy.18  Angiotensin converting enzyme 
inhibitors and β blockers are recommended but may be poorly tolerated 
because of low systemic vascular resistance from diarrheal disease, 
infection or dehydration.  Patients with myocarditis have enhanced 
sensitivity to digoxin and anticoagulation presents risks to patients with 
cerebral vasculopathy and possible aneurysm formation.  The use of 
immunosuppressive regimens is controversial and no convincing benefits 
have been reported other than with intravenous immunoglobulin, 11 whose 
efficacy may reflect inhibition of cardiac auto antibodies by competition 
with Fc receptors or dampened effects of cytokines and cellular growth 
factors. 
ENDOCARDIAL DISEASE 
Three forms of endocarditis have been reported in HIV infected 
patients; marantic (non-bacterial thrombotic), bacterial and fungal. 
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Marantic endocarditis: 
Marantic endocarditis can involve all four cardiac valves, though 
left sided lesions are more common.  Vegetations are friable, consisting 
of platelets within a fibrin mesh with a few inflammatory cells, and 
systemic embolism is common.  The condition, which is usually 
associated with hypercoagulable states in systemic lupus erythematosus, 
disseminated intravascular coagulation, and malignancy, is difficult to 
diagnose ante-mortem.  Identification was frequent in early postmortem 
studies of patients with HIV infection, but the condition is now less 
commonly encountered, suggesting that its prevalence was overestimated 
in the past. 
Bacterial endocarditis: 
Bacterial endocarditis in HIV infection is infrequent, appearing 
almost exclusively in intravenous drug users where prevalence varies 
from 6.3-34%.2 In North America, where most HIV affected patients are 
homosexuals, and endocarditis is uncommon.  Intravenous drug users 
have frequent bacteraemias owing to the introduction of skin pathogens 
and talcum powder by unsterile intravenous injection. Vegetations form 
on the tricuspid and pulmonary valve with resultant pulmonary embolism 
and septic pulmonary infarction.  Patients typically present with fever, 
sweats, weight loss, and co-existing pneumonia and/or meningitis.  
Infection affecting the left heart with systemic embolism is less common.  
Overall incidence of endocarditis in this group is falling; an unexpected 
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benefit of needle exchange and health education schemes, 26 and overdose 
is a more common cause of death.  Staphylococcus aureus is the most 
common organism (>75%) followed by Streptococcus pneumoniae and 
Haemophilus influenzae, although these patients are also at increased risk 
of Salmonella infection.  Methicillin resistant staphylococci have been 
reported, and the HACEK group of organisms (Haemophilus influenzae, 
Haemophilus parainfluenzae, Actinobacillus actinomyceetemcomitans, 
Cardobacterium hominis, Eikenella corrodens, Kingella species) should 
be considered in cases which are resistant to culture.  Austrian’s 
syndrome, characterized by acute streptococcal endocarditis, 
pneumococcal pneumonia, and meningitis, originally described in 
alcoholics, is also more common in AIDS patients. 
Fungal endocarditis: 
Fungal endocarditis is usually the result of systemic fungaemia.  
Aspergillus endocarditis has been reported in association with pulmonary 
aspergillosis, and cryptococcal and candidal endocarditis may complicate 
primary infection in the oropharynx and esophagus, particularly in 
patients nursed on intensive care units. 
Excepting the late stage of AIDS, HIV infection appears to have 
little effect on susceptibility to or mortality from endocarditis, and 
aggressive treatment with conventional antibiotic regimens and surgery 
when required are appropriate.  Medical treatment is successful in > 70% 
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of cases and surgery also has good outcome, provided that intravenous 
drug abuse does not resume in the postoperative period. 
PERICARDIAL DISEASE 
Pericardial disease is a frequent cardiovascular manifestation of 
HIV infection often associated with shortened survival, independent of 
CD4 count and albumin values.6,27 The prevalence of pericardial disease 
at echocardiography ranges from 10-59% and was 21% in the largest 
series of 1139 patients.27 In Africa and many US urban settings, 
pericardial effusion associated with HIV is now the most frequent cause 
of pericardial disease.  The clinical spectrum includes effusions with and 
without cardiac tamponade, constrictive pericarditis and neoplastic 
infiltration by lymphoma and Kaposi’s sarcoma.39  There is no apparent 
correlation between clinical stage of HIV infection and severity of 
pericardial involvement. 
Pericarditis is usually non-specific in origin and can occur with or 
without effusion.  Initial symptoms and signs may be subtle but include 
chest pain and signs of tamponade and hypotension.  Low pressure 
tamponade may be encountered in patients with AIDS who are severely 
dehydrated and cachectic with low resting right ventricular filling 
pressures.  The cause of pericardial effusion is frequently difficult to 
determine though it may be associated with Kaposi’s sarcoma, 
lymphoma, and bacterial 38 (Mycobacterium species, Nocardia species, 
Staphylococcus aureus), viral (herpes simplex, cytomegalovirus virus), 
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and fungal (Cryptococcus neoformans) infection.  In one typical series of 
66 HIV patients with cardiac tamponade, 26% were caused by 
tuberculosis, 17% were purulent, 8% were caused by atypical 
mycobacteria, and 10% by Kaposi’s sarcoma and lymphoma.  HIV itself 
has been isolated from macrophages within the pericardial fluid of one 
patient, though its role remains uncertain.  Culture of pericardial fluid is 
often unrevealing and effusion may be part of generalized serous effusive 
process also involving pleural and peritoneal surfaces, possibly related to 
enhanced expression of cytokines (for example, tumour necrosis factor α) 
in the later stages of HIV disease.6   
Small asymptomatic effusions do not require diagnostic evaluation 
and spontaneously resolve in up to 42% of patients.6 Tuberculosis in 
AIDS is often atypical with a high prevalence of extra pulmonary 
manifestations, and in areas such as Africa where the incidence of 
tuberculous infection is high, patients with pericardial effusion often 
receive empirical anti tuberculous chemotherapy.  Pericardiocentesis is 
currently recommended for patients with large or poorly tolerated 
effusions, diagnostic assessment in the presence of systemic illness, or 
cardiac tamponade.  The effect of HAART on pericardial effusion is 
unknown. 
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MALIGNANT DISEASE 
Two types of malignancy affect the heart in HIV patients: Kaposi’s 
sarcoma, and malignant lymphoma, of which the former is more 
common. 
Kaposi’s sarcoma: 
Kaposi’s sarcoma is a low grade neoplasm arising from 
mesenchymal or endothelial cells and occurs in approximately 30% of 
AIDS patients, mostly male homosexuals.  Cardiac involvement usually 
reflects a widely disseminated process.8 Visceral and parietal pericardial 
lesions are most common though involvement of the myocardium, 
coronary arterial adventitia, great vessels, epicardium, and epicardial fat 
has also been described.  Nodular coalescent dark red or violaceous 
plaques are characteristic and histological examination reveals nodular 
lesions formed by spindle cells surrounding slit-like capillary vessels.  
Cardiac Kaposi’s sarcoma is usually occult and rarely diagnosed during 
life.  Pericardial involvement may rarely manifest as tamponade or 
constriction and underlying myocardial function is rarely affected.39 
Malignant Lymphoma: 
The frequency of non-Hodgkin’s lymphoma in patients with AIDS 
is increasing and estimated to be 25-60 times greater than expected in the 
general population.  Lymphomas are observed in 5-10% of patients 
infected with HIV and constitute the first manifestation of AIDS in 3-4% 
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of new cases.28  Most non-Hodgkin’s lymphomas affecting the heart in 
HIV infection are high grade, with Burkitt-like cells, reticular cell 
sarcomas, or large cell immunoblastic sarcomas.  The majority originates 
from B cells and display monoclonal immunoglobulin staining.  
Pathological examination demonstrates pallor of the heart secondary to 
diffuse lymphomatous infiltration or patchy involvement of the 
epicardium, myocardium, and endocardium in the form of focal 
circumscribed nodules, most frequently affecting the right atrium.  
Histological sections contain infiltrates of plasmacytoid lymphocytic 
cells, resembling immunoblastic non-Hodgkin’s lymphoma, and evidence 
of intense mitotic activity. Extra-nodal sites of lymphoma (typically the 
central nervous system, gastrointestinal tract and bone marrow) are 
common and metastatic cardiac involvement may reflect this 
dissemination.  Secondary cardiac involvement may also arise by direct 
extension of mediastinal mass through the pericardium.  Primary cardiac 
lymphoma is extremely rare but has been reported in patients with HIV. 
Clinical manifestations of cardiac lymphoma include 
cardiomegaly, pericardial effusion, congestive heart failure, arrhythmias 
or progressive heart block.  Sudden death is rare and most patients have 
no evidence of cardiac dysfunction.  Outcome is usually poor and the 
optimal approach to treatment has yet to be determined, though clinical 
remission has been obtained with combination chemotherapy.28  
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DRUGS AND CARDIOTOXICITY 
Until recently, the prognosis of AIDS was so poor that concerns 
about long term effects of drug treatment were minor.  The advent of 
potent antiretroviral drugs has had an impressive effect on mortality, 
disease progression, and incidence of HIV related disorders.  Indeed, HIV 
infection should be considered a chronic condition in an increasing 
proportion of patients, and issues relating to long term drug treatment are 
of increasing relevance.29   
CORONARY DISEASE 
In 1998, severe premature coronary disease was first reported in 2 
young men with HIV infection receiving HAART, specifically Protease 
inhibitors.46   In a retrospective database study  of 36766 HIV patients 
treated at Veterans Affairs facilities between 1993 and 2001, no increase 
in cardiovascular or cerebrovascular events was observed during a mean 
follow  up of 40 months among patients receiving HAART.47 Similarly in 
a meta analysis of 30 randomized clinical trials, the incidence of 
myocardial infarction (MI) was not higher in patients receiving protease 
inhibitors compared with nucleoside reverse-transcriptase inhibitors  ; 
however, the duration of treatment was only 1 year, and the number of 
events was small.48 
On the other hand, in the HIV outpatient Study, myocardial 
infarction (MI) occurred in 19 of 3247 patients taking but in only 2 of 
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2425 not taking Protease inhibitors, and the frequency of MI increased 
after the introduction of these drugs (P=0.0125).40 The Data Collection on 
Adverse Events of Anti- HIV Drugs Study Group prospectively followed 
up 23468 HIV patients for a mean of 1.6 years, with an average exposure 
to antiretroviral therapy of 1.9 years. The risk of MI increased with longer 
exposure to combination antiretroviral therapy; the adjusted relative rate 
per year of exposure was 1.26. In a study of 1551 Italian HIV patients 
followed up for a median of 36 months, 25 coronary events (MI in 13 and 
unstable angina in 12) were diagnosed49. The cumulative annual 
incidence of coronary events was 9.8 per 1000 patients in those treated 
with Protease inhibitors compared with 0.4 per 1000 in those not treated. 
Taken together, these studies suggest that he rate of myocardial 
infarction is higher in HIV patients taking Protease inhibitors and that the 
risk increases as the duration of treatment lengthens.20  The classic 
coronary risk factors usually exert their influence for decades before a 
coronary event occurs.  That an increase in risk can detected after a much 
shorter exposure to Protease inhibitors suggests either that they are a 
potent atherogenic  stimulus or that their use is associated with a period 
of high risk.  The coronary event rates on these studies are relatively low 
but might be expected to be higher as the HIV population ages. 
Clinical Features 
Compared with HIV- uninfected patients, the mean or median age 
of the patients was very young, ranging from a mean or median of 42 to 
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50 years. This was 5 years older than other HIV patients in the French 
cohort study51 and 11 years younger than control non-HIV patients with 
acute coronary syndromes in our study.52 More than half of the patients in 
each of these studies smoked cigarettes at the time of their coronary 
event.  The proportion of patients receiving Protease Inhibitors ranged 
from 49% to 71%. 
Mean HDL cholesterol levels were very low in each of the 3 
studies in which they were reported: 32±10 mg/dl, 50 28±10 mg/dl,51 and 
32±12 mg/dl.52 
These levels were significantly lower than those of HIV patients 
without coronary disease in the French cohort51 and lower than non-HIV 
control subjects with coronary disease in the other two studies. 50,52 Mean 
LDL cholesterol levels were lower in HIV coronary patients than in non-
HIV coronary subjects in one study50 but not another.52 In the French 
cohort, LDL cholesterol levels were much higher in the HIV patients than 
in those without coronary disease.51 
Thus, the typical HIV patient with coronary disease is a male 
smoker with very low HDL cholesterol levels who is significantly 
younger than HIV – uninfected patients with coronary disease.  Coronary 
angioplasty or stenting has often been performed in these patients, and the 
immediate results have been excellent; however. The restenosis rate 
appears to be much higher than that of patients without HIV infection.50, 
52 Atherosclerosis might develop more rapidly in venous bypass grafts in 
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HIV patients because it appears to progress more rapidly in native 
arteries.52 
Cardiomyopathy 
Zidovudine was the first widely available antiretroviral drug and is 
still used in pregnant mothers who are HIV positive (and their newborns) 
and in combination regimens.  Drug induced dilated cardiomyopathy 
secondary to mitochondrial toxicity has been associated with its use in 
adults and children. 
Dyslipidaemia and cardiovascular risk: 
Hyperlipidaemia, hyperglycaemia, hyperinsulinaemia, and 
lipodystropy are frequent adverse effect of potent antiretroviral 
combination therapy, particularly involving protease inhibitors.30 
Hyperlipidaemia affects approximately 50% of patients using protease 
inhibitors, with average increases in total cholesterol and triglyceride 
concentrations of 28% and 96% respectively.  The degree of increase 
seems to be proportional to the duration of treatment and type of drug. 
ATHEROSCLEROSIS IN HIV 
There are several possible explanations for the increase in coronary 
events in HIV patients. Protease inhibitors induce deleterious metabolic 
effects such as dyslipidemia and insulin resistance.42 An alternative 
possibility is that HIV disease is in itself atherogenic.  Progressive HIV 
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disease is associated with accelerated T-cell proliferation, heightened T-
cell activation, and high levels of inflammatory markers. 61, 62.  These 
immunological perturbations persist even after the introduction of 
HAART.63 Indeed, persistent levels of immune activation are observed 
even after years of treatment mediated viral suppression.  The level of 
immune activation has been independently associated with CD4 T-cell 
nadir,64 which was a predictor of progression of Carotid Intima Media 
Thickness.  
Both immunodeficiency and immune reconstitution may be 
atherogenic.  T lymphocytes, of which CD4 cells constitute the major 
population, play a key role in atherogenesis.65, 66 CD4 cell activation 
promotes atherosclerosis through elaboration of proinflammatory 
cytokines, including tumour necrosis factor and interleukins67. 
Analogously, T-cell lymphocytes are also involved in the arteriosclerosis 
that develops in immune – suppressed patients after cardiac 
transplantation.68 
Chronic low – grade inflammation contributes to accelerated 
atherosclerosis.69  C- reactive protein levels are higher in HIV patients 
than in control subjects, and subjects with levels of this marker in the 
upper quartile or quintile have an elevated risk of cardiovascular events.70  
Some experimental data indicate that C-reactive protein is an active 
participant in the process of atherogenesis.71,72 
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 Monocyte chemoattractant protein -- 1 is a potent activator of 
macrophages and monocytes, stimulating them to migrate to the sub 
endothelial space where they begin phagocytosis of modified lipoproteins 
to become lipid-laden foam cells, an early step in atherogenesis.  Among 
HIV patients with sub clinical atherosclerosis by carotid and femoral 
ultrasound, monocyte chemo attractant protein-1 plasma levels were 
higher and the frequency of a mutation in the promoter region of the 
monocyte chemo attractant protein-1 gene was also higher compared with 
HIV patients without atherosclerosis. 
Coagulation  abnormalities that would predispose to thrombotic 
event have been described in HIV patients.73 Protein S deficiency is the 
most common, reported in 73% of HIV infected men in a study.74 Serum 
levels of von Willebrand factor are higher in untreated HIV patients  than 
in control subjects, reflecting endothelial activation, but tend to decrease 
toward normal with HAART.75 Platelet activation is also enhanced in 
HIV patients.56 Platelet activation is also enhanced in HIV patient.75  
Smoking cigarettes activates   platelets and increases coagulability, and 
smoking rates are very high in HIV patients. Endothelial dysfunction13, 
inflammation, platelet activation and hypercoagulability interact 
synergistically to enhance the atherogenic and thrombotic milieu of the 
arterial wall. 
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ENDOTHELIAL DYSFUNCTION IN HIV 
HIV can damage endothelium through several mechanisms. Tat 
protein, a small cationic polypeptide that can be released from infected 
cells, interacts with at least 3 different types of receptors present on the 
surface of   endothelial cells.15,57 The resultant activation of several signal 
transduction pathways triggers the expression of adhesion molecules, 
vascular endothelial growth factor, and platelet activating factor.57 As a 
consequence, Tat protein causes endothelial dysfunction.58 The death of 
CD4 T lymphocytes caused by HIV results in an increase in shed 
membrane particles from these cells.59 Shed membrane particles from T 
lymphocytes induce endothelial dysfunction, expressed as reduction in 
nitric oxide and prostacylin-induced vasodilation.60 
ENDOTHELIAL DYSFUNCTION AND HAART 
 Endothelial dysfunction is a feature of early atherosclerosis and a 
predictor of future cardiovascular events.14,15 HIV infected children have 
endothelial dysfunction compared with age and sex matched control 
subjects in the absence of cardiovascular risk factors.54 The use of 
Protease inhibitors in HIV infected adults is associated with endothelial 
dysfunction as assessed by brachial artery flow mediated vasodilation.55 
This abnormality appears to be mediated by the atherogenic dyslipidemia 
induced by Protease inhibitors.55 
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Soluble adhesion molecules indicative of endothelial damage are 
elevated in HIV infected patients.56 In another study, patient receiving 
HAART had higher levels of P-selectin. Plasminogen activator inhibitor 
type 1, and tissue plasminogen activator but not soluble intracellular 
adhesion molecule-1, and there was no significant difference in the levels 
of these markers between patients receiving Protease inhibitors and non-
Nucleoside reverse transcriptase inhibitors.  
Preliminary guidelines for the evaluation and management of 
dyslipidaemia in HIV positive patients receiving HAART have recently 
been published.31 Key points are routine screening, lifestyle advice 
(including smoking cessation) and comprehensive lipid analysis before 
commencing antiretroviral therapy, and treatment of selected cases.  
Statins which are independent of the cytochrome P450 system (for 
example, pravastatin, atorvastatin) are recommended to avoid interaction 
with protease inhibitors, and use of fibrates and gemfibrozil has been 
described in patients with isolated hypertriglyceridaemia. 
In some patients, with high atherosclerotic co-morbidity or risk, a 
high CD4+ cell count, and low viral load, the risk: benefit ration of 
treatment with HAART may be questionable. 
PULMONARY HYPERTENSION 
Primary pulmonary hypertension has been reported in HIV infected 
patients without evidence of thromboembolic disease, intravenous drug 
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use, right sided endocarditis or pulmonary infection.  Development and 
progression bear no relation to the stage of underlying HIV disease.  It 
affects about 0.5% of hospitalized AIDS patients and is a cause of severe 
cardiac impairment with associated cor pulmonale and death.6 
Histological examination most frequently demonstrates plexogenic 
pulmonary arteriopathy. The pathogenesis is multifactorial and an 
intriguing puzzle: HIV may cause endothelial damage and 
vasoconstriction through release of endothelin-1, interleukin-6, and tumor 
necrosis factor α, oxide anions, and proteolytic enzymes in response to 
infection.24  Therapeutic effects of oxygen, steroids, calcium channel 
blockers, epoprostenol, and nitric oxide have all been proposed though 
efficacy has not been confirmed in controlled clinical trials.33 Effects of 
HAART on pulmonary artery endothelial cells are unknown. 
The effect of antiretroviral treatment on pulmonary hypertension is 
not known.  However, in a recent report from the Swiss Cohort study, 
pulmonary artery pressure increased in untreated patients but decreased in 
patients treated with HAART.79 The oral endothelin receptor antagonist 
bosentan improved exercise tolerance and hemodynamic measurements 
in a small study of HIV patients.80 
With current advances in HIV/AIDS management and increased 
survival, cardiac manifestations of HIV disease will become more 
important and encountered more frequently.  HAART is only available to 
a minority of HIV infected individuals worldwide and studies from the 
 25
pre-HAART period still apply.  Risk factors for vascular disease should 
be monitored in patients receiving HAART.23 
The heart may be a marker of the HIV infected patient’s overall 
health, and a decline in cardiac function should trigger more 
comprehensive evaluation.  As the role of infection and inflammation in 
many other cardiovascular diseases is now recognized, identification of 
the molecular mechanisms of HIV related heart disease may have broader 
implications for a wide range of patients. 
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                            MATERIALS AND METHODS 
The study was performed in the Institute of Internal Medicine, 
Government General Hospital in close association with the Department of 
Cardiology and the Department of Microbiology in the same hospital. 
The study is an observational type of study.  Forty five patients 
who were detected to be HIV positive were included in the study. The 
patients were selected from the inpatient wards of the Institute of Internal 
Medicine, Government General Hospital.  
The HIV serology of the study population was done by double 
Enzyme Linked Immuno-Sorbent Assay (ELISA) using Microwell 
ELISA test at the Department of Microbiology, Government General 
Hospital.  If the ELISA was positive initially, it was repeated twice to 
confirm the HIV seropositive state. 
All patients were:- 
o Questioned for the symptoms suggestive of cardiac illness i.e. chest 
pain, palpitations, shortness of breath, syncope, swelling of lower 
limbs, abdominal distention and decreased urine output.  The 
duration of each symptom was noted. 
o Questioned on the history regarding sexual exposures, abuse of 
intravenous drugs, prior blood transfusions, occupation and marital 
status. 
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o Subjected to detailed and complete general examination for the 
presence of anemia, cyanosis, clubbing, icterus, generalized 
lymphadenopathy and pedal edema.  The pulse, respiration and 
blood pressure were recorded.  A thorough cardiac examination 
which included the jugular venous pressure and waveforms, apical 
impulse, presence of thrill and palpable sounds, the intensity of 
heart sounds, presence of added sounds and murmurs was carried 
out.  The respiratory system, central nervous system and abdomen 
were also examined. 
Complete blood count, blood urea, sugar, serum creatinine, liver 
function tests, urine routine analysis and ultrasonography of the abdomen 
and pelvis were done for all patients.  Fasting serum lipid profile was 
done for patients above the age of forty year.  The CD4 lymphocyte count 
was done at the Department of Microbiology by Flow Cytometry method 
(FACS count equipment, manufactured by B.D.). 
          An erect chest x-ray (postero-anterior view) on deep inspiration 
was taken and analyzed for cardiomegaly, pleural effusions, pulmonary 
hypertension and pulmonary edema.  Chest X-rays were taken using 
100mA x-ray machines manufactured by G.E. at the Barnard Institute of 
Radiology, Government General Hospital 
A standard twelve lead resting electro-cardiogram was done for all 
patients in the Department of Cardiology using Philips ECG machine.  
The various aspects of the P wave and the QRS complexes, ST-T changes 
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and other electro-cardiographic features suggestive of pericarditis, 
myocarditis, pericardial effusion, pulmonary hypertension and left 
ventricular dilatation were noted. 
Two dimensional echocardiography with colour flow Doppler was 
done for all patients in the study at the Department of Cardiology using 
Aloka Equipment.  Echocardiogram was done to evaluate the presence of 
pericardial effusion, chamber dilatation, myocardial dysfunction, ejection 
fraction, pulmonary hypertension and valvular lesions. 
INCLUSION CRITERIA 
HIV seropositive patients; seropositivity being confirmed by 
ELISA at the Department of Microbiology, Government General 
Hospital, Chennai. 
EXCLUSION CRITERIA 
• Patients on treatment with Highly Active Anti-retroviral 
Therapy (HAART). 
• Patients with Hyperlipidemia, Systemic Hypertension, Diabetes 
Mellitus, Ischemic Heart Disease, Rheumatic Heart Disease, 
Congenital Heart Disease and Collagen Vascular Disorders. 
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OBSERVATION 
The study group included 45 patients.  There were 37 (82%) male 
and 8 (18%) female patients.  The study patients fell into the age group 
between 24 and 45 years. 
Of the 45 patients, 22 patients had symptoms referable to the 
cardio-vascular system.  This amounted to 49% of total patients.  The 
common symptoms in decreasing order of frequently are given in the 
table below:- 
Sl.No. SYMPTOMS No. OF PATIENTS 
01 Shortness of Breath 17 
02  Chest Pain 08 
03 Swelling of Lower Limbs 08 
04 Palpitations 07 
05 Decreased Urine Output 06 
 
General examination and clinical examination with relevance to 
cardiac system revealed the following signs as in the table given below:- 
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General Examination 
Sl.No. SIGNS No. OF PATIENTS
01 Oropharyngeal Candidiasis 15 
02 Tachypnea 14 
03 Generalised Lymphadenopathy 11 
04 Pedal Edema 09 
05 Pallor 05 
06 Cyanosis - 
07 Icterus - 
08 Clubbing - 
 
Cardiac Examination 
Sl.No. SIGNS No. OF PATIENTS
01 Tachycardia 18 
02 Elevated JVP 09 
03 Systolic murmur in apex 03 
04 Third Heart Sound 03 
05 Pericardial Rub 03 
06 Loud P2 01 
 
 The most common ECG change observed was Sinus Tachycardia 
seen in 18(40%) patients.  Sinus Tachycardia was not only due to cardiac 
disease but also associated conditions like pulmonary diseases, fever, 
anemia, etc.  The ECG changes observed are given in the table below:- 
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Sl.No. ECG FINDINGS No. OF PATIENTS 
01 Sinus Tachycardia 18 
02 Low Voltage complexes 04 
03 Diffuse ST-T changes 02 
04 P Pulmonale 01 
05 Right Axis Deviation 01 
06 Right Ventricular Hypertrophy 01 
 
 Echocardiogram abnormalities were seen in 12 patients who 
accounted for 27% of the total patients.  The Echocardiographic changes 
in decreasing order of occurrence are given in the table below:- 
Sl.No. ECHO FINDINGS No. OF PATIENTS 
01 Pericardial Effusion 6 
02 Dilated Cardiomyopathy 2 
03 Mild Left Ventricular Dysfunction  2 
04 Pulmonary Hypertension 1 
05 Vegetations over Tricuspid Valve 1 
 
 Nine out of twelve patients with echocardiographically 
demonstrable cardiac lesions had HIV disease for more than 18 months 
duration. All the twelve patients with cardiac lesions 
echocardiographically had CD4 lymphocyte count of less than 250 
cells/mm3. 
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DISCUSSION 
 Cardiac manifestations of HIV infection have not attracted much 
attention because the clinical picture of HIV infection is still dominated 
by opportunistic infections and malignancies.  In this study, 12 patients 
(27%) had some form of cardiac involvement. 
Symptom Analysis: 
In this study, 22 (49%) patients had symptoms referable to cardio 
vascular disease, in the form of breathlessness, palpitations, chest pain, 
swelling of lower limbs, and decreased urine output.  Of this 
breathlessness was the most common symptom encountered in 38% of 
the patients followed by chest pain in 18% of the patients.  Although 
breathlessness and chest pain were considered in the symptoms of cardiac 
disease, their clinical implications must be taken with a degree of caution, 
as they could be attributable to pulmonary and pleural diseases and 
anemia of chronic disease in HIV infection as shown in the study by 
Nzuobontane et al.32 
Pericardial Disease: 
Pericardial disease was observed in 6 (13%) patients in the study.  
In 3 patients, there was only minimal pericardial effusion and these 
patients were followed up.  Repeat echocardiogram after three months 
showed complete resolution of the pericardial effusion in 2 of these 
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patients and in the third patient the effusion completely resolved after five 
months by echocardiogram.  Studies done by Jose Silva-Cardoso et al 34 
showed that 41% of the patients had minimal asymptomatic pericardial 
effusion, 13% had moderate to severe pericardial effusion and 0.55% had 
acute pericarditis. 
One patient with severe pericardial effusion had evidence of 
cardiac tamponade on echocardiogram and so pericardiocentesis was 
done under echocardiographic guidance.  Analysis of the pericardial fluid 
showed it to be a lymphocytic exudative effusion which points to a 
tuberculous etiology.  The patient’s CD4 count was 186cells/mm3 and 
was started on ATT and Efavirenz, Zidovudine and Lamivudine.  Another 
patient with large pericardial effusion presented with TB meningitis.  His 
CD4 count was 171 cells/mm3.  Studies by Steigman, Anderson, Macher 
et al 39 and Karve, Murali, Shah et al 38 reported that tamponade is usually 
associated with pericardial Kaposi’s sarcoma and tuberculous pericarditis.  
Anderson and Virmani et al 53 reported that tamponade and constrictive 
pericarditis accounted for 9.5% of the cardiac deaths. 
Studies done by Rerkpattanapipat, Wongpraparut, Jacobs et al 6 
showed that small asymptomatic effusions do not require diagnostic 
evaluation and spontaneously resolve in up to 42% of patients.  
Pericardiocentesis is currently recommended for patients with large or 
poorly tolerated effusions or cardiac tamponade.   Rerkpattanapipat P et 
al 6 and Heideneich et al27 showed that pericardial disease in HIV 
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infection is often associated with shortened survival, independent of CD4 
count.  Jose Silva-Cardoso et al 34 reported severe pericardial effusions in 
17% of patients with AIDS. 
Electrocardiographic changes in the form of low voltage complexes 
were observed in the three patients with large pericardial effusion and 
their chest X-ray showed cardiomegaly. 
Jose Silva-Cardoso et al 34 reported echogenic mass adherent to the 
visceral pericardium in 3% of the patients.  All these patients had active 
infection in the form of infective endocarditis, pulmonary tuberculosis 
and meningitis.  In this study, none of the patients had either pericardial 
masses or pericarditis on echocardiogram. 
Myocardial Disease 
In this study, five patients(11%) had involvement of the 
myocardium, of which two patients had dilated cardiomyopathy and two 
patients had mild left ventricular dysfunction .  Rerkpattanapipat et al 6 
showed that HIV is the underlying cause in 4% of the patients with 
dilated cardiomyopathy; Milei J et al 7 reported that dilated 
cardiomyopathy affects 10-20% of those with HIV infection and accounts 
for approximately a third of HIV related deaths.  Herskowitz et al 22 in 
another study showed that global left ventricular dysfunction was 
detected by echocardiography in 15% randomly selected HIV patients. 
 
 51
Myocardial biopsy in patients with echocardiographic evidence of 
dilated cardiomyopathy showed that myocarditis was present in 83% of 
patients with dilated cardiomyopathy and co-infection with coxsackie 
virus, cytomegalovirus and Epstein-Barr virus was also noted in many 
cases as shown by Barbaro G et al .37 
In this study, two patients had global hypokinesia of all the four 
chambers and dilated cardiomyopathy with ejection fraction of 32-36% 
which accounted for 4% of the patients.  They had symptoms of 
congestive cardiac failure and opportunistic infections in the form of 
oropharyngeal candidiasis.  One of these patients had HIV associated 
encephalopathy.17  Their chest x-ray showed cardiomegaly and ECG 
showed  sinus tachycardia and low voltage complex in one of patients 
with cardiomyopathy. 
The CD4 counts of patients with dilated cardiomyopathy were 
between 100-150 cells/mm3.  These patients with dilated cardiomyopathy 
were started on HAART, ACE inhibitors and diuretics.  There was no 
improvement in ejection fraction after two months of treatment.  Chariot 
P.et al 35 showed higher frequency of dilated cardiomyopathy in patients 
with CD4 counts less than 100 cells/mm3 indicating an association 
between the degree of immuno-suppression and development of 
cardiomyopathy.  Apart from immuno-suppression, selenium deficiency 
has been identified as a cause of HIV related heart muscle disease by 
Barbaro G et al 37 and Rerkpattanapipat et al.16  Longo-Mbenza et al 19 
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have recently shown, in a study on African patients, that diastolic 
dysfunction that usually precedes systolic dysfunction is an important 
feature of HIV associated heart disease.  Lipschultz et al 9 showed that 
heart failure and left ventricular dysfunction were markers of a dismal 
prognosis. 
Endocardial Disease 
In this study, Infective endocarditis was observed in one patient 
and that patient had history of intravenous drug abuse.  The patient’s 
blood culture grew staphylococcus aureus and echocardiogram showed 
vegetations over the tricuspid valve.  His echocardiogram showed sinus 
Tachycardia.  Patient’s CD4 count was 244 cells/mm3.  He was treated 
with antibiotics.  Barbaro G, Fisher SD and Pellicelli AM et al 2 showed 
that bacterial endocarditis in HIV infection is infrequent and appears 
almost exclusively in intravenous drug users with prevalence of 6.3%-
34%.  The low prevalence of endocardial involvement in this study may 
be related to the low prevalence of intravenous drug abusers in the study 
group. 
Pulmonary Hypertension 
One patient presented with pulmonary hypertension in this study.  
This patient’s electrocardiogram showed ‘P’ pulmonale, right ventricular 
hypertrophy with strain and right axis deviation.  Echocardiogram 
showed severe right atrial and right ventricular dilatation and severe 
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pulmonary hypertension.  Chest x-ray showed a prominent main 
pulmonary trunk.  The patient’s CD4 count was 241 cells/mm3 and was 
given symptomatic treatment.  Studies by Sitbon et al 80 showed that oral 
endothelin receptor antagonist bosentan improved exercise tolerance and 
hemodynamic measurements in HIV patients.  The effects of HAART on 
pulmonary hypertension are unknown and further studies are needed to 
prove its effectiveness.  Recent report from the Swiss Cohort study by 
Zuber et al 79 showed a decrease in the pulmonary artery pressure with 
HAART. 
Changes in the chest x-ray suggestive of cardiac disease were 
observed in 7 (16%) patients.  All the seven patients had 
echocardiographically demonstrable cardiac lesions. 
Electrocardiographic Changes 
Sinus Tachycardia was the most commonly reported ECG 
abnormality in this study, seen in 18(40%) patients.  Sinus Tachycardia 
was not only due to cardiac disease but also associated conditions like 
fever, anemia, pulmonary diseases, etc.  Apart from being associated with 
fever, anemia, overt myocardial dysfunction, isolated persistent 
tachycardia could be an early feature of myocarditis.  Low voltage 
complexes were seen in 4 (9%) patients of whom three patients had 
pericardial effusion and one had cardiomyopathy.  Diffuse ST-T changes 
were seen in two patients.  These patients did not have any cardiac lesion 
by echocardiogram. P Pulmonale and right ventricular hypertrophy with 
right axis deviation was noted in one patient with pulmonary 
hypertension secondary to HIV disease. 
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Only male patients had cardiac manifestations in this study.  This 
may be because of the unequal gender distribution in this study.  But it 
has been hypothesized that HIV infected females live longer than their 
male counterparts.  Further studies are needed to validate this hypothesis. 
Among the HIV positive patients with heart disease, nine patients 
had the disease for more than 18 months.Hence,longer the duration of 
HIV  illness more the chances for the heart to be involved. 
 Individuals in the age group 28-35 years had an increased 
prevalence of cardiac lesions.  The reason for this could be that these 
individuals might have been infected in their twenties and are manifesting 
after an incubation period. 
 All of the subjects were smokers and 20% were alcoholics.  These 
risk factors for heart disease are the same as in general HIV seronegative 
population.  There was no significant increase in incidence of cardiac 
illness in HIV infected individuals with these known atherogenic risk 
factors. 
The limitations of this study are: 
• Unequal representation of males and females. 
• Small sample size. 
• Lack of endomyocardial biopsy studies. 
• Incapability of determining the etiology of pericardial effusions. 
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CONCLUSIONS 
 The prevalence of cardiac disease in HIV positive patients was 
26.6% in this study. 
¾ All patients with symptoms suggestive of heart disease did not 
have cardiac lesions on echocardiogram.  This may be due to the 
fact that symptoms of respiratory diseases and anemia in HIV 
disease can mimic symptoms of heart disease. 
¾ Among the various heart diseases in HIV positive patients, 
pericardial disease was seen in maximum number of patients 
(13%). 
¾ Small asymptomatic pericardial effusions in HIV disease tend to 
resolve spontaneously with time and do not require diagnostic 
evaluation. 
¾ Large pericardial effusions and severe dilated cardiomyopathy in 
HIV disease are usually associated with opportunistic infections 
due to severe immunosuppression. 
¾ The prevalence of heart disease increases with duration of the HIV 
illness. 
¾ Patients with heart diseases can be asymptomatic in early stages of 
the disease so periodic electrocardiographic and echocardiographic 
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evaluation should be done at regular intervals from the time of 
diagnosis of HIV disease. 
¾  All HIV positive patients who had heart disease 
echocardiographically had CD4 counts of less that 250 cells/mm3. 
¾ Early diagnosis and treatment of cardiac lesions could improve the 
quality of life and longevity of HIV infected individual. 
¾ Smoking does not have any increased risk for cardiac disease in 
HIV infected individuals when compared to non HIV general 
population. 
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PROFORMA 
 
HEART DISEASE IN HIV POSITIVE PATIENTS. 
 
Sl. No.      I.P. No. 
 
Name :     Age:   Sex:  
 
Occupation :     Date of Admission: 
 
 
Address :     Date of Discharge: 
 
 
DIAGNOSED HIV POSITIVE IN : 
 
IS THE PATIENT ON HAART : 
 
HISTORY: 
 
01. Breathlessness 
02. Chest Pain 
03. Palpitations 
04. Swelling of Lower Limbs 
05. Abdominal distention 
06. Urine Output 
07. Fever 
08. Cough with expectoration 
09. Other symptoms 
 
PAST HISTORY: 
 
- H/o Diabetes, Hypertension, Tuberculosis, Bronchial Asthma 
- H/o Congenital, Rheumatic, Ischemic Heart Disease 
 
PERSONAL HISTORY: 
 
- H/o Smoking, Alcohol Consumption 
- H/o Sexual Exposure, Blood Transfusions 
- Marital Status 
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CLINICAL EXAMINATION: 
 
- Patient’s General Condition 
- Pulse:  BP:  Respiration:  Temp: 
- J.V.P. 
- Pallor 
- Cyanosis 
- Clubbing 
- Icterus 
- Lymphadenopathy 
- Pedal edema 
 
CARDIAC EXMAINATION: 
- Inspection 
- Palpation 
- Auscultation 
- Other Systems 
 Respiratory 
 Abdomen 
 Central Nervous System 
 
INVESTIGATIONS: 
- Hemogram 
 Hb / PCV 
 TC 
 DC 
 ESR 
 Platelet Count 
- Blood Sugar 
- Urea 
- Creatinine 
- Sodium 
- Potassium 
- Urine routine examination 
- Fasting Lipid Profile 
- CD4 Cell Count 
- Chest x-ray 
- ECG 
- Echo Cardiogram 
- Ultra Sound Abdomen 
- Other Investigations 
TREATMENT GIVEN:
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MASTER  CHART 
 
S. 
No. 
NAME Age 
(years) 
Sex 
Duration 
Since 
diagnosis 
of HIV 
(in months)
Cardiac 
Symptoms 
General 
Examination 
Cardiac 
Examination 
Chest 
X- ray 
(PA view) 
ECG ECHO CD4 
count 
Cell 
/mm3 
1. MUNUSAMY 29/M 22 SOB, 
Chest Pain 
Swelling of  
Lower limbs 
Tachypneic, 
Bipedal 
Edema, 
BP : 90/70 
JVP  
Tachycardia, 
Muffled Heart 
Sounds, 
Pericardial Rub 
Cardiomegaly Low voltage 
complexes. 
 
Large 
pericardial 
effusion with  
Tamponade. 
186 
2. GOVINDHAN 41/M 12 SOB, Pricking 
Chest Pain. 
 
BP: 120/80 
Tachycardia Normal Sinus 
Tachycardia 
Minimal 
Pericardial 
Effusion 
249 
3. KUMARESAN 26/M 12 - - - Normal Normal Normal 392 
4. NAGARAJAN 40/M 14 Chest pain 
(pricking type) 
Fever. 
Tachypneic,  
GL. 
Tachycardia Large Left 
Pleural 
Effusion 
Normal Normal 296 
5. SELVARAJ 31/M 19 SOB, Fever Pallor, 
 
O.C 
JVP  
Tachycardia, 
S1,S2 + 
LV S3 
Pulmonary 
Edema 
Sinus 
Tachycardia 
Normal 350 
6. LOGANATHAN 29/M 5 - - W.N.L 
 
Normal Normal Normal 408 
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7. VENKATESAN 34/M 10 SOB, 
Palpitations 
Tachypneic. 
BP:110/70 
Tachycardia 
S1, S2, 
Bibasilar 
Rules 
Normal Sinus  
Tachycardia 
Mild LV 
Dysfunction 
EF-55 % 
189 
8. LAXMIAMMAL 30/F 12 SOB, Fever Tachypneic, 
OC 
W.N.L Left pleural 
Effusion 
Sinus 
Tachycardia 
Normal 244 
9. RAJU 30/M 24 Pricking 
Chest Pain, 
Palpitations 
BP: 120/80 Tachycardia, 
Pericardial 
Rub. 
Normal Normal Minimal 
Pericardial 
Effusion 
242 
10. KATHIJA BEGUM 26/F 10 - GL, OC. W.N.L Normal Normal Normal 342 
11. ADIAMMAL 25/F 18 Lower limb 
Swelling, 
Decreased urine 
output. 
OC, GL, 
Tachypneic 
Bipedal edema. 
Tachycardia Normal Sinus  
Tachycardia 
Normal 279 
12. RAVI 28/M 8 SOB, chest 
pain, lower 
limb swelling 
Tachypneic, 
Bipedal 
Edema. 
BP: 100/60 
JVP  
Tachycardia, 
Muffled 
Heart Sounds 
Cardiomegaly Low voltage 
Complexes. 
Large 
Pericardial  
Effusion 
171 
13. KANCHANA 30/F 6 SOB, Fever, Tachypneic, 
Pallor, OC. 
 
 
Tachycardia Normal Sinus 
Tachycardia, 
Difuse ST - T 
Changes 
Normal 268 
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14. VEERPANDIAN 31/M 18 SOB, Fever, 
Palpitations, 
Lower Limb 
Swelling, 
decreased 
urine output 
Pallor, 
Tachypneic, 
Pedal edema, 
GL 
BP: 100/70 
JVP  
Tachycardia, 
S1,S2,S3 
PSM in  
Apex 
Pulmonary 
Edema 
Sinus 
Tachycardia 
Vegetations 
over Tricuspid 
Valve. 
244 
15. KUMARAVEL 37/M 10 - - W.N.L Normal Normal Normal 389 
16. ARPUTHARAJ 32/M 4 Fever -           - Normal Normal Normal 402 
17. PANDIAN 26/M 29 SOB, 
Palpitations, 
Lower Limb 
Swelling, 
Decreased urine 
Output . 
Tachypneic, 
Bipedal 
Edema 
BP: 90/60 
JVP  
Tachycardia, 
S1,S2, LVS3, 
Bibasilar  
Rules 
Cardiomegaly, 
Pulmonary 
Edema. 
Sinus 
Tachycardia 
Low voltage 
Complexes 
Dilated 
Cardiomyopathy, 
Global 
Hypokinesia, 
EF-32% 
Sever LV dys 
function 
119 
18. ARUL 36/M 11 Fever, SOB GL,OC. W.N.L B/L 
Infiltrations  
Sinus  
Tachycardia 
 
Normal 298 
19. JOHN WILLIAMS 29/M 26 SOB, 
palpitation 
Tachypneic 
BP: 100/80 
Tachycardia Normal Sinus  
Tachycardia 
Mild L.V 
Dysfunction 
EF – 55% 
151 
20 MANICKAM 33/M 12 - OC, GL W.N.L. Normal Normal Normal 428 
21. KARUPURAJ 31/M 28 SOB, Pricking Tachypneic , JVP  Cardiomegaly Sinus  Large 182 
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Chest Pain OC, BP: 110/80 Tachycardia, 
Muffled Heart 
Sounds, 
Pericardial 
Rub 
Tachycardia, 
Low voltage 
Complexes 
Pericardial 
Effusion, no 
Tamponade. 
22. KOKILA 25/F 2 SOB, Fever OC,GL W.N.L Non 
homogenous 
Opacity right 
Lower zone 
Sinus  
Tachycardia, 
Diffuse ST - T 
Changes 
Normal 298 
23. VAJRAM 27/M 9 - GL,Pallor W.N.L Normal Normal Normal 276 
24. NAZAR  
MOHAMMED 
40/M 12 - - W.N.L Normal Normal Normal 368 
25. SANKAR 35/M 15 - - W.N.L Normal Normal Normal 274 
26. FATHIMA 28/F 9 - - W.N.L Normal Normal Normal 336 
27. ANTONY 36/M 19 S.O.B., Chest 
pain  
          - Tachycardia Normal Sinus 
Tachycardia 
Minimal 
pericardial 
effusion 
245 
28. RAMACHANDRAN 32/M 21 SOB, Swelling 
of Lower Limbs, 
Decreased urine 
output 
OC, 
Bipedal 
Edema 
JVP,Tachycardia Normal Sinus  
Tachycardia 
Normal 406 
29. AYYANAR 27/M 27 -   Emaciated W.N.L Normal Normal Normal 212 
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30. GOVINDARAJ 30/M 13 - Pallor,GL W.N.L Normal Normal Normal 373 
31. LEELAVATHI 24/F 11 - Pallor, 
Emaciated 
W.N.L Normal Normal Normal 291 
32. JANAKIRAM 34/M 24 - OC W.N.L Normal Normal Normal 308 
33. BHAKIYAVATHI 28/F 14  Fever, 
Decreased 
Urine output 
Pedal 
Edema 
W.N.L Normal Sinus 
Tachycardia 
Normal 252 
34. PRAKASH 41/M 11 - - W.N.L Normal Normal Normal 388 
35. SELVAM 25/M 8 - OC W.N.L Normal Normal Normal 352 
36. JAYAKUMAR 29/M 17 Pricking Chest 
Pain, Fever 
G.L., 
Tachypneic 
Tachycardia Right 
Pleural 
effusion 
Sinus 
Tachycardia 
Normal 275 
37. JOHN PETER 25/M 14 - OC, Emaciated W.N.L Normal Normal Normal 358 
38. ABDUL SALAM 32/M 26 SOB, 
Palpitations, 
Lower Limb 
Swelling, 
Decreased 
Urine output 
Tachypneic 
Bipedal 
Edema 
BP:110/70 
JVP  
Tachycardia, 
Loud P2 
PSM in Apex 
Cardiomegaly, 
Prominent 
Main 
Pulmonary 
Trunk, 
pruning of 
peripheral 
Vessels. 
Sinus 
Tachycardia 
Right axis, 
P 
Pulmonale, 
Right 
Ventricular 
Hypertrophy
. 
Right atrial  
and right 
ventricular 
dilatation, 
severe 
Pulmonary 
Hypertension 
Tricuspid 
Regurgitation. 
249 
39. KUPPUSAMY 29/M 14 - - W.N.L Normal Normal Normal 414 
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40. ANANDRAJ 32/M 18 - OC,GL W.N.L Normal Normal Normal 398 
41. THIRUVENGADAM 29/M 21 - OC W.N.L Normal Normal Normal 422 
42. VANDEVAN 36/M 13 - - W.N.L Normal Normal Normal 378 
43. MUNIAPPAN 35/M 36 SOB, 
Palpitations, 
Lower limb  
swelling 
Tachypneic 
Pedal edema, 
BP: 100/70 
JVP 
Tachycardia, 
S1,S2, 
PSM in apex 
Bibasilar rales. 
Cardiomegaly, 
Pulmonary 
Edema. 
Sinus 
Tachycardia 
 
Dilated cardio 
myopathy, 
Global 
Hypokinesia, 
Severe LV 
Dysfunction 
EF –36% 
Trivial Mitral 
Regurgitation 
108 
44. SATHIYARAJ 31/M 9 - - W.N.L Normal Normal Normal 458 
45. FRANCIS 33/M 14 - - W.N.L Normal Normal Normal 302 
 
ABBREVIATIONS 
M-MALE     GL- GENERALISED LYMPHADENOPATHY PSM- PAN SYSTOLIC MURMUR 
F- FEMALE     JVP – JUGULAR VENOUS PULSE   EF – EJECTION FRACTION 
WNL – WITHIN NORMAL LIMITS BP- BLOOD PRESSURE 
OC – ORAL CANDIDIASIS   LV- LEFT VENTRICLE. 
 
